Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Net Margin (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Net Margin for 15 consecutive years, with 2972.43% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 483751.0% to 2972.43% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 7736.26% through Dec 2025, down 109079.0% year-over-year, with the annual reading at 7736.26% for FY2025, 108106.0% down from the prior year.
  • Net Margin hit 2972.43% in Q4 2025 for Cardiff Oncology, up from 9386.67% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 2972.43% in Q4 2025 to a low of 14863.51% in Q1 2022.
  • Historically, Net Margin has averaged 8737.44% across 5 years, with a median of 7927.64% in 2024.
  • Biggest five-year swings in Net Margin: crashed -766212bps in 2022 and later skyrocketed 864257bps in 2024.
  • Year by year, Net Margin stood at 7103.76% in 2021, then increased by 4bps to 6799.22% in 2022, then rose by 12bps to 5989.1% in 2023, then crashed by -30bps to 7809.93% in 2024, then surged by 62bps to 2972.43% in 2025.
  • Business Quant data shows Net Margin for CRDF at 2972.43% in Q4 2025, 9386.67% in Q3 2025, and 11528.1% in Q2 2025.